For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| MCI/OSA/CPAP Adherent | Device: CPAP. Included those diagnosed with MCI and OSA. The diagnostic criteria for OSA was defined as an AHI score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. | 0 | None | 5 | 29 | 0 | 29 | View |
| MCI/OSA/CPAP Non-adherent | Device: CPAP. Included those diagnosed with MCI and OSA. The diagnostic criteria for OSA was defined as an AHI score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. | 0 | None | 0 | 25 | 0 | 25 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Heart irregularities | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Bleeding | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | None | View |
| Surgery | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Hospital admission | SYSTEMATIC_ASSESSMENT | General disorders | None | View |